Literature DB >> 11686105

Congenital von Willebrand disease type 3: clinical manifestations, pathophysiology and molecular biology.

J C Eikenboom1.   

Abstract

von Willebrand disease type 3 is the most severe form of this condition. Patients present with a moderate-to-severe bleeding tendency. The plasma von Willebrand factor level in these patients is very low or undetectable. Although rare, von Willebrand disease type 3 is of major interest because of its severe clinical presentation, the need for replacement therapy and the risk of occurrence of alloantibodies after the infusion of plasma concentrates. The inheritance of type 3 disease is typically autosomal recessive. The parents are often consanguineous, although compound heterozygous inheritance does occur. The molecular basis of von Willebrand disease type 3 has recently been studied in detail, several molecular defects being identified. This chapter will focus on the clinical and molecular aspects of type 3 von Willebrand disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11686105     DOI: 10.1053/beha.2001.0139

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN: 1521-6926            Impact factor:   3.020


  12 in total

1.  Clinical and laboratory versus molecular markers for a correct classification of von Willebrand disease.

Authors:  Augusto B Federici; Maria T Canciani
Journal:  Haematologica       Date:  2009-05       Impact factor: 9.941

2.  Translational medicine advances in von Willebrand disease.

Authors:  D Lillicrap
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

Review 3.  Diagnostic approach to von Willebrand disease.

Authors:  Christopher Ng; David G Motto; Jorge Di Paola
Journal:  Blood       Date:  2015-02-23       Impact factor: 22.113

Review 4.  von Willebrand disease: clinical and laboratory lessons learned from the large von Willebrand disease studies.

Authors:  Paula D James; David Lillicrap
Journal:  Am J Hematol       Date:  2012-03-03       Impact factor: 10.047

5.  Intracellular storage and regulated secretion of von Willebrand factor in quantitative von Willebrand disease.

Authors:  Jiong-Wei Wang; Karine M Valentijn; Hetty C de Boer; Richard J Dirven; Anton Jan van Zonneveld; Abraham J Koster; Jan Voorberg; Pieter H Reitsma; Jeroen Eikenboom
Journal:  J Biol Chem       Date:  2011-05-19       Impact factor: 5.157

6.  von Willebrand factor variant p.Arg924Gln marks an allele associated with reduced von Willebrand factor and factor VIII levels.

Authors:  N Hickson; D Hampshire; P Winship; J Goudemand; R Schneppenheim; U Budde; G Castaman; F Rodeghiero; A B Federici; P James; I Peake; J Eikenboom; A Goodeve
Journal:  J Thromb Haemost       Date:  2010-09       Impact factor: 5.824

7.  The genetics of Canadian type 3 von Willebrand disease: further evidence for co-dominant inheritance of mutant alleles.

Authors:  M Bowman; A Tuttle; C Notley; C Brown; S Tinlin; M Deforest; J Leggo; V S Blanchette; D Lillicrap; P James
Journal:  J Thromb Haemost       Date:  2013-03       Impact factor: 5.824

Review 8.  The molecular characterization of von Willebrand disease: good in parts.

Authors:  P D James; D Lillicrap
Journal:  Br J Haematol       Date:  2013-02-14       Impact factor: 6.998

Review 9.  von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy.

Authors:  David Lillicrap
Journal:  Blood       Date:  2013-09-24       Impact factor: 22.113

10.  Genotypes of European and Iranian patients with type 3 von Willebrand disease enrolled in 3WINTERS-IPS.

Authors:  Luciano Baronciani; Ian Peake; Reinhard Schneppenheim; Anne Goodeve; Minoo Ahmadinejad; Zahra Badiee; Mohammad-Reza Baghaipour; Olga Benitez; Imre Bodó; Ulrich Budde; Andrea Cairo; Giancarlo Castaman; Peyman Eshghi; Jenny Goudemand; Wolf Hassenpflug; Hamid Hoorfar; Mehran Karimi; Bijan Keikhaei; Riitta Lassila; Frank W G Leebeek; Maria Fernanda Lopez Fernandez; Pier Mannuccio Mannucci; Renato Marino; Nikolas Nikšić; Florian Oyen; Cristina Santoro; Andreas Tiede; Gholamreza Toogeh; Alberto Tosetto; Marc Trossaert; Eva M K Zetterberg; Jeroen Eikenboom; Augusto B Federici; Flora Peyvandi
Journal:  Blood Adv       Date:  2021-08-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.